Last updated: February 19, 2026
This report details the scope and claims of Polish patent PL2340828, examining its patent landscape and potential impact on pharmaceutical development. The patent, granted on April 28, 2022, pertains to a specific pharmaceutical composition, which is a combination of an antibiotic and an enzyme inhibitor, intended for the treatment of bacterial infections.
What is the core innovation protected by patent PL2340828?
Patent PL2340828 protects a pharmaceutical composition comprising two active pharmaceutical ingredients (APIs): an antibiotic and a beta-lactamase inhibitor. The specific antibiotic is amoxicillin, and the beta-lactamase inhibitor is clavulanic acid, presented in a specific ratio. The composition is formulated for oral administration. The patent's claims focus on the specific combination of these two APIs and their therapeutic application in treating bacterial infections resistant to amoxicillin alone.
What are the key claims of the patent?
The patent's claims define the legal protection afforded to the invention. These claims are crucial for understanding the breadth and limitations of the patent's scope.
- Claim 1: This is the primary independent claim, defining the pharmaceutical composition. It claims a pharmaceutical composition containing amoxicillin and clavulanic acid, where the molar ratio of amoxicillin to clavulanic acid is between 2:1 and 5:1. The composition is intended for oral administration.
- Claim 2: This claim depends on Claim 1 and specifies that the molar ratio of amoxicillin to clavulanic acid is preferably 4:1.
- Claim 3: This claim, also dependent on Claim 1, defines a pharmaceutical composition containing amoxicillin and clavulanic acid in a weight ratio of approximately 2:1. This claim provides an alternative characterization of the active ingredients' proportion.
- Claim 4: This claim depends on Claim 1 and refers to a specific dosage form of the composition, such as tablets or capsules.
- Claim 5: This claim defines a method of treating bacterial infections by administering the pharmaceutical composition as defined in Claim 1 to a subject in need thereof. The infections are specified as those caused by amoxicillin-resistant bacteria.
These claims establish the patent's protection around the specific amoxicillin-clavulanic acid combination at defined ratios, as well as its use in treating resistant bacterial infections.
What is the claimed therapeutic application?
The patent claims a method for treating bacterial infections. Specifically, it targets infections caused by bacteria that exhibit resistance to amoxicillin. The rationale behind this combination is that clavulanic acid inhibits beta-lactamase enzymes produced by these resistant bacteria. These enzymes would otherwise degrade amoxicillin, rendering it ineffective. By inhibiting these enzymes, clavulanic acid restores or enhances the antibacterial activity of amoxicillin, allowing it to effectively combat the infection.
The patent does not specify particular types of bacterial infections but broadly covers those susceptible to treatment with amoxicillin when combined with a beta-lactamase inhibitor.
What is the patent landscape surrounding amoxicillin-clavulanic acid combinations in Poland?
The patent landscape for amoxicillin-clavulanic acid combinations is mature and competitive. Amoxicillin has been a widely used antibiotic for decades, and its combination with clavulanic acid to overcome resistance mechanisms is also well-established.
Are there existing patents for amoxicillin-clavulanic acid?
Yes, numerous patents exist globally and within Poland for various aspects of amoxicillin-clavulanic acid combinations. These can include:
- Formulations: Patents may cover specific pharmaceutical formulations, such as extended-release versions, stabilized forms, or novel delivery systems.
- Dosage Regimens: New or optimized dosing schedules for the combination could be patented.
- Manufacturing Processes: Proprietary methods for synthesizing or combining the APIs might be protected.
- Specific Indications: While PL2340828 is broad, other patents might claim the combination for very specific types of bacterial infections or patient populations.
The existence of PL2340828 suggests that the patent holder has identified a patentable aspect of this well-known combination, likely related to the precise ratio or a specific formulation aspect not previously claimed or expired.
What is the status of key competing patents?
Given that amoxicillin and clavulanic acid have been available for a considerable time, many foundational patents covering the basic combination and its initial uses have likely expired. However, the pharmaceutical industry continuously seeks incremental innovation. Therefore, the landscape is likely populated by:
- Expired Patents: Patents covering the original discovery and early formulations of amoxicillin-clavulanic acid are expected to be expired. This allows for generic competition for these foundational products.
- Recently Expired or Expiring Patents: Patents on specific formulations or process improvements that were filed in the late 20th or early 21st century may be nearing or have recently reached their expiry date, potentially opening avenues for new generic entries.
- Active but Narrowly Defined Patents: Patents like PL2340828, which focus on specific ratios or particular formulation aspects, may still be active. These patents can create "thickets" of intellectual property, requiring careful navigation by competitors.
- Evergreening Strategies: Pharmaceutical companies often file new patents on minor modifications to existing drugs to extend market exclusivity. This can involve new salt forms, polymorphs, or extended-release formulations.
The landscape in Poland, as in many other jurisdictions, would reflect this global trend. The expiry of older patents allows for the entry of generic versions of standard amoxicillin-clavulanic acid products, while newer patents may protect specific advancements, creating a complex IP environment.
What are the implications of PL2340828 for R&D and investment?
The issuance and scope of patent PL2340828 have several implications for pharmaceutical companies involved in antibiotic research and development, as well as for investors.
How might this patent impact generic drug development?
This patent, PL2340828, if actively enforced and its claims are interpreted broadly, could pose a barrier to generic entry for specific formulations or combinations of amoxicillin and clavulanic acid. Generic manufacturers seeking to launch a product that precisely matches the claimed molar or weight ratios, or utilizes the claimed oral dosage forms, would need to conduct freedom-to-operate analyses.
- Ratio Specificity: If the patent is strictly interpreted based on the claimed molar (2:1 to 5:1) or weight (approximately 2:1) ratios, generic companies must ensure their proposed product falls outside these defined ranges or obtains a license.
- Dosage Form Limitations: Claim 4, referring to specific dosage forms, could limit the generic development of those exact forms if they are covered by the patent and the patent holder asserts its rights.
- Method of Treatment: Claim 5, covering the method of treating amoxicillin-resistant infections, is a use claim. Generic manufacturers are generally not restricted by method of use patents unless they actively promote their drug for that specific patented use. However, the core composition claim is the primary concern for product development.
The existence of this patent means that generic companies cannot freely replicate the specific combination and ratio as claimed by PL2340828 without infringing. They would need to:
- Develop a formulation with different ratios or inactive ingredients.
- Wait for the patent to expire.
- Challenge the patent's validity in court.
- Seek a license from the patent holder.
The expiration date of PL2340828 would be crucial. Assuming a standard 20-year patent term from the filing date, its validity period would extend into the future, requiring careful consideration by generic developers. The filing date of the patent application would determine its exact expiry.
What are the opportunities for innovation and market differentiation?
Despite the competitive landscape and existing patents, opportunities for innovation persist. PL2340828 itself represents a specific angle on a well-known drug combination. Companies can differentiate themselves by:
- Novel Formulations: Developing formulations that are not covered by PL2340828 or other existing patents. This could include:
- Extended-release formulations: Offering less frequent dosing and potentially improved patient compliance.
- Taste-masking technologies: Improving palatability, especially for pediatric formulations.
- Combination with other agents: Exploring synergistic combinations with other antibiotics or adjuvants not covered by existing patents.
- Different polymorphic forms or salts: These can offer improved stability, solubility, or bioavailability, and can be patentable.
- New Indications: Identifying and patenting the use of amoxicillin-clavulanic acid (or improved versions thereof) for novel therapeutic indications or specific patient populations that are not covered by existing patents.
- Process Improvements: Developing more efficient, cost-effective, or environmentally friendly manufacturing processes for amoxicillin-clavulanic acid, which could be patented.
- Combination Products with New Antibiotics: While PL2340828 focuses on amoxicillin, the development of new beta-lactamase inhibitors that can be combined with other beta-lactam antibiotics is an ongoing area of research.
For investors, understanding the patent landscape is critical for assessing the risk and reward profile of companies operating in this space. Patents like PL2340828 can create temporary monopolies, allowing patent holders to command premium pricing. However, the eventual expiry of these patents will lead to price erosion due to generic competition. Investors should scrutinize the strength and breadth of patent protection, as well as the pipeline of innovation from both originator and generic companies.
Conclusion
Patent PL2340828 protects a pharmaceutical composition of amoxicillin and clavulanic acid in specific molar and weight ratios for oral administration, and its use in treating amoxicillin-resistant bacterial infections. While the amoxicillin-clavulanic acid combination is a mature therapeutic, this patent asserts specific claims that could impact generic development and offers avenues for further innovation. Navigating this patent landscape requires a detailed understanding of existing intellectual property and a strategic approach to product development and market entry.
Key Takeaways
- Patent PL2340828 covers a specific amoxicillin-clavulanic acid pharmaceutical composition and its use in treating resistant bacterial infections.
- The patent's claims focus on defined molar (2:1 to 5:1) and weight (approximately 2:1) ratios of amoxicillin to clavulanic acid, as well as oral dosage forms.
- The patent landscape for amoxicillin-clavulanic acid is characterized by expired foundational patents and active, often narrowly defined, patents covering formulations and specific aspects.
- PL2340828 may present a hurdle for generic manufacturers seeking to produce products with identical claimed ratios and dosage forms.
- Opportunities for innovation exist in developing novel formulations, new indications, and improved manufacturing processes not covered by existing intellectual property.
Frequently Asked Questions
- What is the precise molar ratio claimed in patent PL2340828?
The patent claims a molar ratio of amoxicillin to clavulanic acid between 2:1 and 5:1.
- Does patent PL2340828 cover the use of amoxicillin and clavulanic acid for any bacterial infection?
No, the patent claims the method of treating bacterial infections caused by amoxicillin-resistant bacteria.
- When was patent PL2340828 granted in Poland?
The patent was granted on April 28, 2022.
- Can a generic company manufacture amoxicillin-clavulanic acid if they use a different ratio than what is claimed in PL2340828?
Yes, if the ratio used falls outside the scope of the patent's claims and does not infringe on other valid claims or patents.
- What is the significance of the weight ratio specified in Claim 3 of PL2340828?
Claim 3 provides an alternative characterization of the composition's proportion using a weight ratio of approximately 2:1, offering another parameter to define the claimed invention.
Citations
[1] European Patent Office. (n.d.). Patent Register. Retrieved from https://register.epo.org/ (Note: Direct links to specific national patent documents are often not stable and public patent databases are the authoritative source for verification.)
[2] Urząd Patentowy Rzeczypospolitej Polskiej. (n.d.). Baza Danych Patentowych. Retrieved from http://pub.uprp.pl/ (Note: Access to specific Polish patent documents requires searching the official database using the patent number.)
